LRP1 and Hyperglycemia: The results showed OCN AAV-shRNA-injected LRP1 eKO mice displayed severe hyperglycemia, displaying a reverse response to the normalized non-fasting glucose level in LRP1 eKO mice following STZ injection (Fig. 7d).